Alzheimer's disease (AD) is the most common neurological disorder in people over the age
of 65. It has been estimated that in 2010 there were 4.7 million individuals aged 65 years or …

Purpose The aim of the present study was to prepare a patient friendly long acting donepezil
(D) nanocrystals (NCs) formulation, with a high payload for im administration. As the native …

Objective The primary objective of this study was to develop nanostructured lipid carriers of
donepezil hydrochloride (DNZ HCl) for effective management of Alzheimer's disease (AD) …

This review covers nanotherapeutic strategies for solving the global problems associated
with Alzheimer's disease (AD). The most dramatic factor contributing humanistic, social and …

Introduction Donepezil (DPL), a specific acetylcholinesterase inhibitor, is used as a first-line
treatment to improve cognitive deficits in Alzheimer's disease (AD) and it might have a …

Treatment of brain diseases is always limited by the physiological nature of the highly
selective blood‐brain barrier (BBB) and the electrostatic charge of the nanoporous …

Alzheimer's disease (AD) is a multifactorial neurodegenerative central system disease with a
high prevalence among the elderly and is the most common form of dementia. Oxidative …

Alzheimer's disease (AD) is a form of dementia with high impact worldwide, accounting with
more than 46 million cases. It is estimated that the number of patients will be four times …

Alzheimer's disease and Parkinson's disease are the most common neurodegenerative
diseases worldwide. Despite all the efforts made by the scientific community, current …

Recently, the development of nanotechnology and nanomaterial has promoted extremely
the application of drug delivery systems in the biomedical field. However, the drug delivery …